Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Inhibition of v-Abl transformation in 3T3 cells overexpressing different forms of the Abelson interactor protein Abi-1

Oncogene volume 20, pages 4926–4934 (2001)Cite this article

Abstract

The abi-1 gene encodes a protein that binds and is phosphorylated by the Abelson protein tyrosine kinase. Constructs expressing a full-length abi-1 cDNA, and a smaller cDNA arising from an alternatively spliced form, were generated and tested for their effect on transformation of NIH3T3 cells by the Abelson murine leukemia virus. Overexpression of both forms of the protein strongly inhibited transformation by the wild-type P160 strain of the virus, but not by the non-interacting mutant P90A strain. The inhibition required the SH3 domain of Abi-1, suggesting that a direct interaction was required for the effect. Rare breakthrough P160 transformants of the Abi-1 overexpressing lines were found to have downregulated Abi-1 protein levels by a post-transcriptional mechanism.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Abelson HT, Rabstein LS . 1970 Cancer Res. 30: 2213–2222

  • Bergold PJ, Blumenthal JA, Andrea ED, Snyder HW, Lederman L, Silverstone A, Nguyen H, Besmer P . 1987 J. Virol. 61: 1193–1202

  • Biesova Z, Piccoli C, Wong WT . 1997 Oncogene 14: 233–241

  • Carpino N, Wisniewski D, Strife A, Marshak D, Kobayashi R, Stillman B, Clarkson B . 1997 Cell 88: 197–204

  • Dai Z, Pendergast AM . 1995 Genes Dev. 9: 2569–2582

  • Dai Z, Quackenbush RC, Courtney KD, Grove M, Cortez D, Reuther GW, Pendergast AM . 1998 Genes Dev. 12: 1415–1424

  • Danial NN, Losman JA, Lu T, Yip N, Krishnan K, Krolewski J, Goff SP, Wang JY, Rothman PB . 1998 Mol. Cell. Biol. 18: 6795–6804

  • de Klein A, van Kellel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, Spurr NK, Heisterkamp N, Groffen J, Stephenson JR . 1982 Nature 300: 765–767

  • Fan P-D, Goff SP . 2000 Mol. Cell. Biol. 20: 7591–7601

  • Fazioli F, Minicheillo L, Matoska V, Castagnino P, Miki T, Wong WT, Di Fiore PP . 1993 EMBO J. 12: 3799–3808

  • Goff SP, Witte ON, Gilboa E, Rosenberg N, Baltimore D . 1981 J. Virol. 38: 460–468

  • Juang JL, Hoffmann FM . 1999 Oncogene 18: 5138–5147

  • Kinsella TM, Nolan GP . 1996 Hum. Gene. Ther. 7: 1405–1413

  • Maniatis T, Fristch EF, Sambrook J . 1982 Molecular cloning, a laboratory manual Cold Spring Harbor, Cold Spring Harbor, NY

    Google Scholar 

  • McWhirter JR, Wang JY . 1993 EMBO J. 12: 1533–1546

  • Murtagh K, Skladany G, Hoag J, Rosenberg N . 1986 J. Virol. 60: 599–606

  • Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW . 1994 Blood 84: 2912–2918

  • Raffel G, Parmar K, Rosenberg N . 1996 J. Biol. Chem. 271: 4640–4645

  • Ren R, Ye ZS, Baltimore D . 1994 Genes Dev. 8: 783–795

  • Rosenberg N, Witte ON . 1980 J. Virol. 33: 340–348

  • Sawyers CL, McLaughlin J, Witte ON . 1995 J. Exp. Med. 181: 307–313

  • Scita G, Nordstrom J, Carbone R, Tenca P, Giardina G, Gutkind S, Bjarnegard M, Betsholtz C, Di Fiore PP . 1999 Nature 401: 290–293

  • Shi Y, Alin K, Goff SP . 1995 Genes Dev. 9: 2583–2597

  • So C, So C, Cheung N, Chew S, Sham M, Chan L . 2000 Leukemia 14: 594–601

  • Taki T, Shibuya N, Taniwaki M, Hanada R, Morishita K, Bessho F, Yanagisawa M, Hayashi Y . 1998 Blood 92: 1125–1130

  • Van Etten RA . 1999 Trends Cell. Biol. 9: 179–186

  • Van Etten RA, Jackson PK, Baltimore D, Sanders MC, Matsudaira PT, Janmey PA . 1994 J. Cell. Biol. 124: 325–340

  • Wen ST, Van Etten RA . 1997 Genes Dev. 11: 2456–2467

  • Yamanashi Y, Baltimore D . 1997 Cell 88: 205–211

Download references

Acknowledgements

This work was supported by Public Health Service grant P01 CA 23767 from the National Cancer Institute. H-Y Yang and G Gao are Associates, and SP Goff is an Investigator of the Howard Hughes Medical Institute.

Author information

Authors and Affiliations

  1. Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, 10032, NY, USA

    Alexandra Ikeguchi

  2. Department of Biochemistry and Molecular Biophysics, Howard Hughes Medical Institute, Columbia University, College of Physicians and Surgeons, New York, 10032, NY, USA

    Hen-Ying Yang, Guangxia Gao & Stephen P Goff

Authors
  1. Alexandra Ikeguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hen-Ying Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guangxia Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stephen P Goff
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ikeguchi, A., Yang, HY., Gao, G. et al. Inhibition of v-Abl transformation in 3T3 cells overexpressing different forms of the Abelson interactor protein Abi-1. Oncogene 20, 4926–4934 (2001). https://doi.org/10.1038/sj.onc.1204502

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204502

Keywords

This article is cited by

Search

Advanced search

Quick links